I really liked everyone’s points about documentation and risk management. One thing I’d add is the importance of continuous feedback loops within each phase rather than relying only on formal phase-gate reviews. If “Check” and “Act” are happening throughout the…   Read more»

I agree with everyone’s points about version control and centralized systems. One thing that stands out to me is that this issue can be procedural and cultural, and not just technical. Even with a document control system in place, if…   Read more»

Reading everyone’s responses, one thing that stands out is how verification failures often expose issues beyond just the test itself. Whether it’s component selection, manufacturability, tolerancing, or scalability, verification seems to be the point where design assumptions are finally stress-tested…   Read more»

When animal study results conflict with the original project plan, a project manager has to prioritize patient safety and long-term device performance over market deadlines. In this case, even though the bio-absorbable stent is technically safe, dissolving too quickly means…   Read more»

One thing I’ve noticed is that the right developmental life cycle often depends less on the industry and more on how mature the requirements and risk profile are at a given stage. In medical devices, teams often label a project…   Read more»

One thing I’d add is that a strong DHF isn’t just about having all the right documents, it’s also about showing clear traceability and change control throughout the project. Design changes can’t be avoided, and if updates to user needs,…   Read more»

One additional factor that influences a medical device’s product life cycle is how well design transfer and manufacturing readiness are handled early on. Even if a device performs well during development, poor translation of design specifications into manufacturing processes can…   Read more»

I think the threshold for moving from repeated verification iterations to a formal scope change should be based less on the number of failures and more on whether the proposed fix introduces new regulatory or documentation requirements. If addressing a…   Read more»

One angle I haven’t seen discussed yet is how much the intended use and claims of a device can influence whether a company ends up on the PMA or 510(k) pathway, sometimes more than the technology itself. From the lecture,…   Read more»

I think one of the most effective ways for project managers to work within the FDA’s constraints is by involving regulatory considerations early on, instead of treating them as something to deal with at the very end. From the lecture,…   Read more»

A lot of great points here focus on communication, prioritization, and technical awareness, but one skill I think ties all of those together is decision-making under uncertainty. In biomedical projects, PMs rarely have perfect information. Clinical data evolves, regulatory feedback…   Read more»

One thing I haven’t seen discussed yet is how the best background for a medical device PM might actually depend on what stage of the product lifecycle the project is in. Early on, when concepts are still being refined, a…   Read more»

Another angle is that ongoing conflict can sometimes point to a process issue rather than a people issue. If a project manager and a highly skilled team member keep clashing, it may mean there isn’t a clear or consistent way…   Read more»

One issue I see with depending too much on FMEAs is that they are predicated on the idea that failures occur one component at a time in predictable ways. However, contemporary medical devices do not malfunction in neat, linear sequences,…   Read more»

One thing that often gets overlooked is that risk isn’t just tied to the device design but it’s tied to the patient using it. Two people with the same pacemaker can have completely different reactions due to comorbidities, genetics, drug…   Read more»

Sometimes a mitigation doesn’t make the product safer overall, it just transfers the risk to a different user group, workflow, or failure mode. For ex., adding too many alarms on a medical device can reduce one specific hazard, but it…   Read more»

Everyone’s shared great technical solutions, but another issue behind documentation fatigue is how people interact with the process, not just the tools themselves. When updates feel like busywork instead of part of the project’s story, engagement drops.   Organizations could…   Read more»

Everyone’s made great points about prediction limits and company oversight. Another major gap is that verification and validation don’t really reflect real-life patient diversity. The DePuy implants may have passed lab tests, but they didn’t consider how factors like bone…   Read more»

While many have raised valid points about adaptive algorithms and overconfidence in structured systems, I think a modern “Therac moment” could result less from technical gaps and more from ethical and organizational blind spots. Current design controls ensure functional safety,…   Read more»

I agree with everyone that design controls don’t have to kill creativity – it really depends on how teams use them. One idea I haven’t seen mentioned yet is how design controls can work alongside agile methods. Some med-tech startups…   Read more»